SCHEMBL4489557

SCHEMBL4489557

Cc1nc(-c2cccc(-c3ccc(C(F)(F)F)cc3C(F)(F)F)c2)n[nH]1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 4/20 0.44
SCN9A Q15858 4/20 0.44
ABCC8 Q09428 1/20 0.41
KCNJ11 Q14654 1/20 0.41
IKBKB O14920 1/20 0.40
TRPA1 O75762 1/20 0.38
ALOX5AP P20292 1/20 0.38
FEN1 P39748 1/20 0.38
KDR P35968 1/20 0.38
CYP1A2 P05177 2/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
IDO1 P14902 1/20 0.37
LRRK2 Q5S007 1/20 0.37
HDAC3 O15379 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
NCOR2 Q9Y618 1/20 0.36
EDNRB P24530 1/20 0.36
EDNRA P25101 1/20 0.36
MAPK14 Q16539 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4484659 0.86 TRPA1 (0.52) CYP2C9SCN9ATRPA1CYP1A2
SCHEMBL13754837 0.81 TRPA1 (0.50) CYP2C9SCN9ATRPA1CYP1A2MAPK14
SCHEMBL4564282 0.80 SCN9A (0.50) CYP2C9SCN9AABCC8KCNJ11ALOX5AP
SCHEMBL4495572 0.77 ALOX5AP (0.42) CYP2C9SCN9AABCC8KCNJ11ALOX5AP
SCHEMBL25011712 0.75 CYP2C9 (0.50) CYP2C9SCN9AALOX5APFEN1CYP3A4
SCHEMBL1041002 0.75 HDAC3 (0.55) HDAC3HDAC6NCOR2
SCHEMBL1400156 0.72 SCN9A (0.60) CYP2C9SCN9ATRPA1CYP3A4CYP2D6
SCHEMBL13754839 0.72 BRD4 (0.53) SCN9AALOX5APFEN1KDRSCN5A
SCHEMBL24017179 0.72 SCN9A (0.44) CYP2C9SCN9AALOX5APFEN1EDNRB
SCHEMBL25407073 0.72 IKBKB (0.49) CYP2C9IKBKBCYP1A2IDO1HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572822-B2 Biaryl substituted triazoles as sodium channel blockers MERCK & CO. INC. (US) 2009-08-11 US disclosed
US-7572822-B2 Biaryl substituted triazoles as sodium channel blockers MERCK & CO. INC. (US) 2009-08-11 US disclosed
EP-1606269-B1 BIARYL SUBSTITUTED TRIAZOLES AS SODIUM CHANNEL BLOCKERS MERCK & CO INC (US) 2008-10-29 EP disclosed
EP-1606269-B1 BIARYL SUBSTITUTED TRIAZOLES AS SODIUM CHANNEL BLOCKERS MERCK & CO INC (US) 2008-10-29 EP disclosed
US-20080171777-A1 Biaryl substituted triazoles as sodium channel blockers MERCK SHARP & DOHME LLC 2008-07-17 US disclosed
US-20080171777-A1 Biaryl substituted triazoles as sodium channel blockers MERCK SHARP & DOHME LLC 2008-07-17 US disclosed
US-7326726-B2 Biaryl substituted triazoles as sodium channel blockers MERCK & CO., INC. (US) 2008-02-05 US disclosed
US-7326726-B2 Biaryl substituted triazoles as sodium channel blockers MERCK & CO., INC. (US) 2008-02-05 US disclosed
US-20060183897-A1 Biaryl substituted triazoles as sodium channel blockers MERCK & CO., INC. 2006-08-17 US disclosed
US-20050119261-A1 Biaryl substituted triazoles as sodium channnel blockers MERCK SHARP & DOHME LLC 2005-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171777-A1 Biaryl substituted triazoles as sodium channel blockers SCN3A, TRPV1, SCN1B CYP2C9 349/4885SCN9A 56/4885ABCC8 1220/4885
US-20050119261-A1 Biaryl substituted triazoles as sodium channnel blockers SCN3A, TRPV1, KCNN3 CYP2C9 279/4885SCN9A 67/4885ABCC8 665/4885
US-20060183897-A1 Biaryl substituted triazoles as sodium channel blockers SCN3A, TRPV1, SCN1B CYP2C9 349/4885SCN9A 56/4885ABCC8 1220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.